367 related articles for article (PubMed ID: 37119690)
1. Targeting Myc-driven stress addiction in colorectal cancer.
Saeed H; Leibowitz BJ; Zhang L; Yu J
Drug Resist Updat; 2023 Jul; 69():100963. PubMed ID: 37119690
[TBL] [Abstract][Full Text] [Related]
2. Deptor Is a Novel Target of Wnt/β-Catenin/c-Myc and Contributes to Colorectal Cancer Cell Growth.
Wang Q; Zhou Y; Rychahou P; Harris JW; Zaytseva YY; Liu J; Wang C; Weiss HL; Liu C; Lee EY; Evers BM
Cancer Res; 2018 Jun; 78(12):3163-3175. PubMed ID: 29666061
[TBL] [Abstract][Full Text] [Related]
3. MYC and metabolism on the path to cancer.
Hsieh AL; Walton ZE; Altman BJ; Stine ZE; Dang CV
Semin Cell Dev Biol; 2015 Jul; 43():11-21. PubMed ID: 26277543
[TBL] [Abstract][Full Text] [Related]
4. Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells.
Tögel L; Nightingale R; Chueh AC; Jayachandran A; Tran H; Phesse T; Wu R; Sieber OM; Arango D; Dhillon AS; Dawson MA; Diez-Dacal B; Gahman TC; Filippakopoulos P; Shiau AK; Mariadason JM
Mol Cancer Ther; 2016 Jun; 15(6):1217-26. PubMed ID: 26983878
[TBL] [Abstract][Full Text] [Related]
5. Targeting Translation Initiation Bypasses Signaling Crosstalk Mechanisms That Maintain High MYC Levels in Colorectal Cancer.
Wiegering A; Uthe FW; Jamieson T; Ruoss Y; Hüttenrauch M; Küspert M; Pfann C; Nixon C; Herold S; Walz S; Taranets L; Germer CT; Rosenwald A; Sansom OJ; Eilers M
Cancer Discov; 2015 Jul; 5(7):768-781. PubMed ID: 25934076
[TBL] [Abstract][Full Text] [Related]
6. [c-MYC-mediated regulations in colorectal cancer].
Menssen A
Pathologe; 2013 Nov; 34 Suppl 2():274-6. PubMed ID: 24196628
[TBL] [Abstract][Full Text] [Related]
7. Rewired Metabolism Caused by the Oncogenic Deregulation of MYC as an Attractive Therapeutic Target in Cancers.
Vízkeleti L; Spisák S
Cells; 2023 Jun; 12(13):. PubMed ID: 37443779
[TBL] [Abstract][Full Text] [Related]
8. The AURKA/TPX2 axis drives colon tumorigenesis cooperatively with MYC.
Takahashi Y; Sheridan P; Niida A; Sawada G; Uchi R; Mizuno H; Kurashige J; Sugimachi K; Sasaki S; Shimada Y; Hase K; Kusunoki M; Kudo S; Watanabe M; Yamada K; Sugihara K; Yamamoto H; Suzuki A; Doki Y; Miyano S; Mori M; Mimori K
Ann Oncol; 2015 May; 26(5):935-942. PubMed ID: 25632068
[TBL] [Abstract][Full Text] [Related]
9. MYC, Metabolism, and Cancer.
Stine ZE; Walton ZE; Altman BJ; Hsieh AL; Dang CV
Cancer Discov; 2015 Oct; 5(10):1024-39. PubMed ID: 26382145
[TBL] [Abstract][Full Text] [Related]
10. Elevated protein expression of cyclin D1 and Fra-1 but decreased expression of c-Myc in human colorectal adenocarcinomas overexpressing beta-catenin.
Wang HL; Wang J; Xiao SY; Haydon R; Stoiber D; He TC; Bissonnette M; Hart J
Int J Cancer; 2002 Oct; 101(4):301-10. PubMed ID: 12209953
[TBL] [Abstract][Full Text] [Related]
11. Targeting MYC Translation in Colorectal Cancer.
Castell A; Larsson LG
Cancer Discov; 2015 Jul; 5(7):701-3. PubMed ID: 26152922
[TBL] [Abstract][Full Text] [Related]
12. FoxO3a confers cetuximab resistance in RAS wild-type metastatic colorectal cancer through c-Myc.
Yu Y; Guo M; Wei Y; Yu S; Li H; Wang Y; Xu X; Cui Y; Tian J; Liang L; Peng K; Liu T
Oncotarget; 2016 Dec; 7(49):80888-80900. PubMed ID: 27825133
[TBL] [Abstract][Full Text] [Related]
13. The Endosomal Protein CEMIP Links WNT Signaling to MEK1-ERK1/2 Activation in Selumetinib-Resistant Intestinal Organoids.
Duong HQ; Nemazanyy I; Rambow F; Tang SC; Delaunay S; Tharun L; Florin A; Büttner R; Vandaele D; Close P; Marine JC; Shostak K; Chariot A
Cancer Res; 2018 Aug; 78(16):4533-4548. PubMed ID: 29915160
[TBL] [Abstract][Full Text] [Related]
14. Emerging Roles of C-Myc in Cancer Stem Cell-Related Signaling and Resistance to Cancer Chemotherapy: A Potential Therapeutic Target Against Colorectal Cancer.
Elbadawy M; Usui T; Yamawaki H; Sasaki K
Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31083525
[TBL] [Abstract][Full Text] [Related]
15. PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy.
Tan J; Li Z; Lee PL; Guan P; Aau MY; Lee ST; Feng M; Lim CZ; Lee EY; Wee ZN; Lim YC; Karuturi RK; Yu Q
Cancer Discov; 2013 Oct; 3(10):1156-71. PubMed ID: 23887393
[TBL] [Abstract][Full Text] [Related]
16. Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity.
Kim J; Roh M; Abdulkadir SA
BMC Cancer; 2010 Jun; 10():248. PubMed ID: 20515470
[TBL] [Abstract][Full Text] [Related]
17. Mission Possible: Advances in MYC Therapeutic Targeting in Cancer.
Allen-Petersen BL; Sears RC
BioDrugs; 2019 Oct; 33(5):539-553. PubMed ID: 31392631
[TBL] [Abstract][Full Text] [Related]
18. Tumor suppressor NDRG2 inhibits glycolysis and glutaminolysis in colorectal cancer cells by repressing c-Myc expression.
Xu X; Li J; Sun X; Guo Y; Chu D; Wei L; Li X; Yang G; Liu X; Yao L; Zhang J; Shen L
Oncotarget; 2015 Sep; 6(28):26161-76. PubMed ID: 26317652
[TBL] [Abstract][Full Text] [Related]
19. Regulation of cancer cell metabolism: oncogenic MYC in the driver's seat.
Dong Y; Tu R; Liu H; Qing G
Signal Transduct Target Ther; 2020 Jul; 5(1):124. PubMed ID: 32651356
[TBL] [Abstract][Full Text] [Related]
20. Myc coordinates transcription and translation to enhance transformation and suppress invasiveness.
Elkon R; Loayza-Puch F; Korkmaz G; Lopes R; van Breugel PC; Bleijerveld OB; Altelaar AF; Wolf E; Lorenzin F; Eilers M; Agami R
EMBO Rep; 2015 Dec; 16(12):1723-36. PubMed ID: 26538417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
